Myostatin Inhibitors: Follistatin-344 & ACE-031

Myostatin inhibitors are the most genetically seductive idea in the muscle-building world. Knock out a single growth-limiting protein and animals — and a handful of rare humans — grow visibly more muscle without lifting a weight. That observation is real, reproducible, and decades old. So the obvious question follows: can a peptide or biologic do the same thing in a healthy adult who wants to get bigger?

The honest headline, stated first so nothing below is misread: the muscle-growth biology of myostatin inhibition is genuine, but the drugs built on it have repeatedly stalled in human trials — and the lead injectable, ACE-031, was halted after subjects developed dose-dependent bleeding and dilated small blood vessels. "Follistatin-344" and similar peptides sold to lifters are unapproved research chemicals with essentially no controlled human data behind the marketing, and every compound in this class is banned at all times in tested sport under WADA. This article separates the proven biology from the unproven (and in places unsafe) products.

What Myostatin Actually Does

Myostatin — also called GDF-8 — is a member of the TGF-beta protein family that acts as a brake on skeletal-muscle growth. When researchers deleted the myostatin gene in mice, the animals grew two to three times the normal muscle mass; the protein's entire job is to limit how big muscles get¹. The same loss-of-function story appears across species: cattle breeds with myostatin mutations show the "double-muscling" phenotype, with dramatically enlarged muscles tied directly to mutations in the gene².

Most strikingly, it happens in humans. A child with a naturally occurring myostatin mutation was reported with gross muscle hypertrophy and unusual strength, confirming that the brake exists in people, not just livestock³. That single case report is the foundation the entire "block myostatin, build muscle" industry stands on.

So the mechanism is not a marketing invention. Lowering myostatin signaling really does release a growth constraint. The hard part — the part the supplement market skips — is doing that safely and effectively with a drug in a normal adult.

The Two Things People Mean by "Myostatin Inhibitor Peptides"

When lifters search for myostatin inhibitors, they usually mean one of two very different things.

Soluble decoy receptors like ACE-031 (ramatercept) are engineered biologics, not small peptides. ACE-031 is a soluble form of the activin receptor type IIB (ActRIIB) fused to an antibody fragment — a "ligand trap" that mops up myostatin (and several related proteins) before they can reach the real receptor on muscle. This is the most clinically advanced approach, and the one with actual human trial data.

Follistatin is a natural protein that binds and neutralizes myostatin and related ligands directly⁴. "Follistatin-344" and "follistatin-315" are the names attached to grey-market injectable products and to gene-therapy constructs. The follistatin sold to bodybuilders is a research chemical with no published controlled human trial of injected follistatin peptide for muscle gain in healthy people; the only human follistatin data come from gene-therapy studies in muscular dystrophy, not from the vials lifters buy.

A useful distinction: the compounds with real human data (ActRIIB traps, follistatin gene therapy) are biologics studied in disease, while the compounds sold to athletes ("follistatin-344" peptide) are exactly the ones with no controlled human evidence behind them.

What the Human Trials Actually Found

Here is where the seductive biology meets a wall.

ACE-031 is the most informative case because it was tested in people. In a randomized, placebo-controlled trial in ambulatory boys with Duchenne muscular dystrophy — a population that desperately needs more muscle — the trial was stopped early because of safety findings, before efficacy could be established⁵. The signal that triggered the halt had already appeared in healthy volunteers: in a single-ascending-dose study, ACE-031 produced dose-dependent adverse effects including small dilated blood vessels in the skin (telangiectasias), nosebleeds (epistaxis), and gum bleeding⁶. Those vascular and bleeding effects — thought to reflect the ActRIIB trap hitting ligands beyond myostatin — are why the program did not continue. The lean-mass changes seen with the class were modest, and they came tethered to a safety problem serious enough to end development.

That pattern — real but small muscle gains, offset by off-target effects — recurs across the class. A review of myostatin inhibitors for musculoskeletal disorders concluded that despite a compelling rationale, the clinical results have been underwhelming, with multiple agents failing to translate the dramatic animal phenotype into meaningful, safe human benefit⁷. A broader survey of myostatin from basic biology to clinical application reaches the same sober verdict: the pathway is validated, but turning it into an approved muscle-building drug has proven far harder than the mouse data predicted⁸.

Follistatin's human evidence is even thinner and confined to disease. A phase 1/2a follistatin gene-therapy trial in Becker muscular dystrophy delivered the follistatin gene by viral vector and reported some functional improvement in a small, uncontrolled cohort⁹ — a genuine early-stage result, but one that says nothing about whether an injected "follistatin-344" peptide bought online builds muscle in a healthy lifter. There is no such trial. The leap from "gene therapy helped a handful of dystrophy patients" to "this peptide will add slabs of muscle to a healthy adult" is exactly the kind of extrapolation honest reading should reject.

Why "It Works in Mice" Keeps Failing in People

The recurring error is treating a powerful animal phenotype as a finished human product. Myostatin knockout doubles muscle in a mouse, and a rare human mutation produces a strong, muscular child — both true¹³. Neither sentence says a drug given to a normal adult safely reproduces that effect.

Two problems break the chain. First, the receptor traps are not clean: ActRIIB binds activins and other TGF-beta ligands that regulate blood vessels and other tissues, which is the most likely explanation for the bleeding and telangiectasias that halted ACE-031⁶. Blocking a growth brake everywhere is not the same as building muscle in one place. Second, lifelong genetic absence of myostatin during development is not the same as transiently lowering it in an adult who already finished growing — the dramatic phenotypes come from animals and people who never had normal myostatin, not from a course of injections.

The result is the same surrogate-versus-outcome trap that runs through this whole category, the one we lay out in our review of peptides for muscle growth: a real mechanism, a real biomarker or animal effect, and an absent — or unsafe — human outcome. A closely related cautionary tale is IGF-1 LR3, another "build muscle by hijacking a growth pathway" product whose evidence is animal-only and whose cancer signal makes the risk-benefit worse, not better. We apply the same skepticism across our pillar on peptides for recovery and healing.

The Anti-Doping and Quality Reality

For any drug-tested athlete this debate is moot. Myostatin inhibitors — including ActRIIB traps, follistatin products, and anti-myostatin agents — fall squarely under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), which explicitly names agents that affect muscle through the myostatin pathway, banned at all times, in and out of competition¹⁰. Anti-doping science has actively developed detection methods for this class, including serum-biomarker approaches aimed at the myostatin/follistatin axis — part of the broader detection picture we cover in what the WADA 2026 Prohibited List changed for peptides. A positive test is an anti-doping rule violation.

The supply problem compounds it. None of these compounds is an FDA-approved drug, and the FDA has moved peptides of this kind off the list of substances pharmacies may freely compound, citing limited safety data and the difficulty of controlling peptide identity and purity¹¹. "Follistatin-344" is sold "for research use only" by grey-market vendors, so a buyer cannot verify what is in the vial, at what dose, or whether it is sterile — on top of a benefit that was never demonstrated in a controlled human trial. Stacking an unverifiable injectable onto an unproven mechanism is not a hack; it is two risks multiplied. For a fuller comparison of these research chemicals against the other major grey-market muscle category, see our honest peptides vs SARMs breakdown.

Bottom Line

The biology of myostatin inhibition is one of the best-validated muscle-growth mechanisms in science: delete the gene and animals — and a rare human — grow far more muscle. But the drugs built on it have not delivered a safe, proven muscle benefit in normal adults. ACE-031, the most advanced candidate, was halted after subjects developed bleeding and dilated blood vessels, and reviews of the whole class describe its clinical results as underwhelming. "Follistatin-344" sold to lifters has no controlled human trial behind it at all — only disease gene-therapy data that does not transfer to healthy people.

The honest position is neither "this is the future of muscle" nor "it does nothing." It is this: the mechanism is real, the human muscle benefit is unproven, the lead drug's safety signal was real enough to stop a trial, and every compound here is an unapproved research chemical that is banned in tested sport. For the proven (and unexciting) muscle levers, return to our review of peptides for muscle growth, weigh the category against SARMs for recovery and muscle, and see our ranking of vetted recovery peptide providers.